{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.16","upperLimit":"16.00","value":"13.73"},{"groupId":"OG001","lowerLimit":"9.10","upperLimit":"16.23","value":"13.14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"384"},{"groupId":"OG001","value":"193"}],"units":"Participants"}],"description":"The OS is defined as the time from the date of first dose of study drug to date of death from any cause. If the participant is alive or the vital status is unknown, the participant will be censored at the date the participant will be last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Trabectedin at a dose of 1.5 milligram per meter square (mg/m\\^2) was given as an intravenous (IV) infusion over 24-hour every 3 weeks on Day 1 of every cycle (21 days) until disease progression. Dexamethasone 20 mg IV was also administered within 30 minutes before start of each trabectedin infusion.","id":"OG000","title":"Trabectedin"},{"description":"Dacarbazine at a dose of 1 gram per meter square (mg/m\\^2) was given as an intravenous (IV) infusion over 20-120 minutes every 3 weeks on Day 1 of every cycle (21 days) until disease progression. Dexamethasone 20 mg IV was also administered within 30 minutes before start of each dacarbazine infusion.","id":"OG001","title":"Dacarbazine"}],"paramType":"MEDIAN","populationDescription":"Analysis population included all the randomized participants up to up to final analysis cut-off date (05 January 2015).","reportingStatus":"POSTED","timeFrame":"approximately 3 years 8 months (From Study start date [27 May 2011] up to final analysis data cut-off [05 January 2015]","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}